WEC
NKTR icon

Winslow Evans & Crocker’s Nektar Therapeutics NKTR Stock Holding History

Winslow Evans & Crocker’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20
Closed -$31.9K – 1151
2018
Q1 		$31.9K Hold
20
– – 0.01% 569
2017
Q4 		$17.9K Hold
20
– – 0.01% 681
2017
Q3 		$7.2K Hold
20
– – ﹤0.01% 872
2017
Q2 		$5.87K Hold
20
– – ﹤0.01% 1032
2017
Q1 		$7.04K Buy
+20
New +$4.5K ﹤0.01% 965

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Winslow Evans & Crocker's NKTR Position: Q2 2018 in Review

Winslow Evans & Crocker sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 20 shares — an estimated $31.9K sold.

Winslow Evans & Crocker first reported a position in NKTR in Q1 2017 and held it in 5 quarters. The position peaked at $31.9K in Q1 2018. 378 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Winslow Evans & Crocker reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Winslow Evans & Crocker sold 20 Nektar Therapeutics shares in Q2 2018, an estimated $31.9K.
  • Winslow Evans & Crocker first reported a position in Nektar Therapeutics in Q1 2017 and held it in 5 quarters.
  • Winslow Evans & Crocker's Nektar Therapeutics position peaked at $31.9K in Q1 2018.
  • 378 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Winslow Evans & Crocker's 13F filing for Q2 2018, filed 17 Jul 2018.